Lorenz Muller Sells 53,566 Shares of Milestone Pharmaceuticals (NASDAQ:MIST) Stock

Milestone Pharmaceuticals Inc. (NASDAQ:MIST) insider Lorenz Muller sold 53,566 shares of Milestone Pharmaceuticals stock in a transaction dated Monday, December 15th. The stock was sold at an average price of $2.32, for a total value of $124,273.12. Following the completion of the transaction, the insider directly owned 196,486 shares of the company’s stock, valued at approximately $455,847.52. This trade represents a 21.42% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link.

Lorenz Muller also recently made the following trade(s):

• On Monday, January 26th, Lorenz Muller sold 11,180 shares of Milestone Pharmaceuticals stock. The shares were sold at an average price of $1.93, for a total value of $21,577.40.

Milestone Pharmaceuticals Trading Down 2.6%

NASDAQ MIST opened at $1.89 on Friday. The stock has a market capitalization of $160.97 million, a P/E ratio of -2.30 and a beta of 0.44. The business has a 50 day simple moving average of $2.23 and a 200 day simple moving average of $1.96. The company has a debt-to-equity ratio of 2.74, a current ratio of 8.24 and a quick ratio of 8.24. Milestone Pharmaceuticals Inc. has a one year low of $0.63 and a one year high of $3.06.

Milestone Pharmaceuticals (NASDAQ:MIST) last posted its quarterly earnings results on Wednesday, November 12th. The company reported ($0.12) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.17) by $0.05. Research analysts expect that Milestone Pharmaceuticals Inc. will post -0.62 earnings per share for the current year.

Key Milestone Pharmaceuticals News

Here are the key news stories impacting Milestone Pharmaceuticals this week:

• Positive Sentiment: Milestone announced U.S. pharmacy availability of its CARDAMYST nasal spray — a commercial launch that begins the company’s transition from development to product revenue and increases commercial visibility. Read More.
• Positive Sentiment: Zacks Research upgraded MIST from “Hold” to “Strong Buy,” which can attract short?term buyers and momentum flows into a thinly traded microcap. Read More.
• Neutral Sentiment: Technical/trading context is mixed: shares sit below the 50?day moving average and current volume is below the stock’s average, which may limit a sustained rally despite the launch and upgrade.
• Negative Sentiment: CEO Joseph Oliveto executed large sales (133,054 shares on Dec. 15 at ~$2.32 and 34,523 shares on Jan. 26 at ~$1.93). Material insider reductions by the CEO often trigger investor concern about insider conviction and can add selling pressure. Read More.
• Negative Sentiment: Other senior insiders (COO Jeffrey Nelson, and executives David Bharucha and Lorenz Muller) also sold large blocks on Dec. 15 and Jan. 26, representing double?digit percentage cuts to their stakes—a clustered pattern that intensifies negative sentiment and helps explain downward pressure on the share price. Read More. Read More. Read More.

Institutional Trading of Milestone Pharmaceuticals

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Sapient Capital LLC purchased a new stake in shares of Milestone Pharmaceuticals in the third quarter worth approximately $25,000. Bank of America Corp DE grew its holdings in Milestone Pharmaceuticals by 200,550.0% during the third quarter. Bank of America Corp DE now owns 16,052 shares of the company’s stock worth $32,000 after buying an additional 16,044 shares in the last quarter. Stephenson & Company Inc. bought a new stake in Milestone Pharmaceuticals during the third quarter worth $40,000. Creative Planning raised its position in Milestone Pharmaceuticals by 74.6% in the 2nd quarter. Creative Planning now owns 23,410 shares of the company’s stock valued at $45,000 after buying an additional 10,000 shares during the last quarter. Finally, Bay Rivers Group raised its position in Milestone Pharmaceuticals by 72.9% in the 4th quarter. Bay Rivers Group now owns 28,861 shares of the company’s stock valued at $58,000 after buying an additional 12,170 shares during the last quarter. 86.18% of the stock is owned by institutional investors.

Analyst Ratings Changes

Several brokerages have recently weighed in on MIST. Zacks Research upgraded shares of Milestone Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a report on Monday. Wall Street Zen downgraded Milestone Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Saturday, January 10th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Milestone Pharmaceuticals in a report on Monday, December 29th. TD Cowen raised Milestone Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Monday, December 15th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $8.00 target price on shares of Milestone Pharmaceuticals in a research report on Tuesday, January 6th. One research analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $8.00.

Milestone Pharmaceuticals Company Profile

Milestone Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on developing innovative therapies for respiratory diseases. The company’s research emphasizes both biologic and small-molecule approaches designed to improve mucociliary clearance, reduce airway inflammation and address chronic and refractory cough. Milestone’s pipeline targets key underserved conditions such as cystic fibrosis, primary ciliary dyskinesia and severe asthma.

Milestone’s lead product candidates are delivered through inhalation or systemic administration, reflecting the company’s commitment to optimizing therapeutic delivery directly to the lungs.